Aspira Womens Health Inc AWH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AWH is a good fit for your portfolio.
News
-
Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California
-
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
-
Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
-
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
-
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
-
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
-
Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
-
Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
Trading Information
- Previous Close Price
- $3.28
- Day Range
- $3.23–3.45
- 52-Week Range
- $2.31–6.75
- Bid/Ask
- $3.32 / $3.33
- Market Cap
- $41.06 Mil
- Volume/Avg
- 16,905 / 23,230
Key Statistics
- Price/Earnings (Normalized)
- 0.11
- Price/Sales
- 3.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 64
- Website
- https://www.aspirawh.com
Valuation
|
Metric
|
AWH
|
|---|---|
Price/Earnings (Normalized) | 0.11 |
Price/Book Value | — |
Price/Sales | 3.36 |
Price/Cash Flow | — |
Price/Earnings
AWH
Financial Strength
|
Metric
|
AWH
|
|---|---|
Quick Ratio | 0.79 |
Current Ratio | 1.03 |
Interest Coverage | — |
Quick Ratio
AWH
Profitability
|
Metric
|
AWH
|
|---|---|
Return on Assets (Normalized) | −160.80% |
Return on Equity (Normalized) | −1,947.23% |
Return on Invested Capital (Normalized) | −434.88% |
Return on Assets
AWH
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Shfpwhwwh | Gczk | $209.3 Bil | |
DHR
| Danaher Corp | Sbvwpfyp | Ywcfnh | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Gdwxbqsb | Hlfkxks | $42.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Drspynnt | Slnkqwm | $41.5 Bil | |
A
| Agilent Technologies Inc | Dgsjkgjqy | Rnyzt | $40.4 Bil | |
MTD
| Mettler-Toledo International Inc | Sglbjwgbv | Sqvxgd | $26.5 Bil | |
ICLR
| Icon PLC | Fmjhcml | Qjczzc | $24.8 Bil | |
ILMN
| Illumina Inc | Ykqwkkm | Dtqcvby | $19.5 Bil | |
WAT
| Waters Corp | Prppzkqqv | Kyp | $18.5 Bil | |
LH
| Laboratory Corp of America Holdings | Ybrjdbpqg | Lmpxml | $16.7 Bil |